Zai Lab Limited

AI Score

0

Unlock

24.28
-0.93 (-3.69%)
At close: Jan 14, 2025, 3:59 PM
24.29
0.04%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 23.8
Market Cap 2.64B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.8
PE Ratio (ttm) -8.67
Forward PE n/a
Analyst Buy
Ask 25.6
Volume 353,874
Avg. Volume (20D) 943,622
Open 25.21
Previous Close 25.21
Day's Range 24.26 - 25.64
52-Week Range 13.48 - 36.60
Beta undefined

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and ...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 2,175
Stock Exchange NASDAQ
Ticker Symbol ZLAB

Analyst Forecast

According to 3 analyst ratings, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 126.52% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Zai Lab Limited is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $110.52M, reflecting a 67.89% YoY growth and earnings per share of -0.78, making a -20.41% decrease YoY.
2 months ago · Source
+1.46%
Zai Lab shares are trading higher. The company pri... Unlock content with Pro Subscription
2 months ago · Source
-10.95%
Zai Labs shares are trading lower after the company announced a $200 million proposed public offering.